Navigating Care and Safety

Managing DPM3-CDG focuses on supporting specific symptoms and preventing complications. Because this is an ultra-rare condition, there is currently no established, FDA-approved disease-modifying therapy or “cure” that fixes the underlying genetic change ^[1]. Instead, care is “phenotype-driven,” meaning your medical team will create a plan based on how the condition affects the muscles, heart, and brain ^[2][3].

Your Multidisciplinary Care Team

Because DPM3-CDG can affect multiple systems, you will likely work with a coordinated team of specialists ^[2]:

• Neuromuscular Specialist: A neurologist who focuses on muscle health, tracking strength and monitoring for seizures or developmental needs ^[2].
• Cardiologist: A heart specialist who performs baseline and individualized routine screenings to watch for dilated cardiomyopathy, managing it with standard heart-failure medications or rhythm monitoring if it emerges ^[4].
• Metabolic Geneticist: A doctor who specializes in disorders of glycosylation and can help coordinate overall care and genetic counseling ^[3].
• Therapy Team: Physical therapists (PT) to maintain safe mobility, occupational therapists (OT) for daily living skills, and speech-language pathologists (SLP) for challenges with speaking or swallowing ^[5].

The Truth About Supplements

In some other types of Congenital Disorders of Glycosylation (CDG), specialized sugars like mannose or galactose are used as treatments ^[6][7]. However, it is important to know that these supplements have not been proven effective for DPM3-CDG ^[3].

While research is ongoing, these sugars are currently considered experimental for this specific condition. You should only consider these or other supplements under the direct guidance of a metabolic specialist, as they can have side effects and may not provide the benefits seen in other CDG types ^[3][1].

Essential Safety: Anesthesia and Surgery

If you or your child needs surgery requiring sedation, you must inform the anesthesiology team about the DPM3-CDG diagnosis well in advance. Patients with neuromuscular conditions and dystroglycanopathies face specific risks during anesthesia ^[8]:

• Rhabdomyolysis Risk: The muscle relaxant succinylcholine is generally avoided in known muscular dystrophies due to the risk of hyperkalemia and a dangerous breakdown of muscle tissue known as rhabdomyolysis ^[8][9]. Volatile anesthetics (inhaled gases) also carry risks that should be carefully discussed.
• Pain Management: Doctors use individualized dosing and vigilant postoperative respiratory monitoring with opioid-based pain relievers because they can cause unpredictable breathing problems (respiratory depression) in patients with weakened muscles ^[8].
• Safer Alternatives: The anesthesiologist will determine the safest approach, which may include “Total intravenous anesthesia” (TIVA) ^[8]. Carry a medical alert card, but never delay emergency surgery while seeking an anesthesia letter.

Supportive Therapies and Monitoring

Regular follow-up is the cornerstone of care for DPM3-CDG. This typically includes:

1. Cardiac Screening: Baseline check-ups and individualized follow-up intervals with an ECG and echocardiogram (ultrasound of the heart) to catch early signs of heart weakening ^[10].
2. Respiratory Care: Monitoring for signs of breathing weakness during sleep or a weakened cough, which may require help from a pulmonologist ^[11].
3. Physical Activity: Exercise should be individualized with a neuromuscular physical therapist, avoiding excessive eccentric or “no pain, no gain” exercise unless recommended by the care team.
4. Nutrition and Swallowing: If muscle weakness affects the ability to chew or swallow safely, a nutritionist or speech therapist can help with diet textures or specialized feeding support ^[5].